These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 20847059)

  • 1. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
    Carr LL; Mankoff DA; Goulart BH; Eaton KD; Capell PT; Kell EM; Bauman JE; Martins RG
    Clin Cancer Res; 2010 Nov; 16(21):5260-8. PubMed ID: 20847059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
    J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.
    Gkountouvas A; Kostoglou-Athanassiou I; Veniou E; Repousis P; Ziras N; Kaldrimidis P
    Thyroid; 2010 Jun; 20(6):597-600. PubMed ID: 20553195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
    Bikas A; Kundra P; Desale S; Mete M; O'Keefe K; Clark BG; Wray L; Gandhi R; Barett C; Jelinek JS; Wexler JA; Wartofsky L; Burman KD
    Eur J Endocrinol; 2016 Mar; 174(3):373-80. PubMed ID: 26671977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
    Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
    Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
    J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
    Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
    Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.
    Díez JJ; Iglesias P; Alonso T; Grande E
    Endocrine; 2015 Mar; 48(2):582-8. PubMed ID: 25030550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.
    Salaun PY; Campion L; Ansquer C; Frampas E; Mathieu C; Robin P; Bournaud C; Vuillez JP; Taieb D; Rousseau C; Drui D; Mirallié E; Borson-Chazot F; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1501-10. PubMed ID: 24806110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
    Marotta V; Ramundo V; Camera L; Del Prete M; Fonti R; Esposito R; Palmieri G; Salvatore M; Vitale M; Colao A; Faggiano A
    Clin Endocrinol (Oxf); 2013 May; 78(5):760-7. PubMed ID: 23009688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
    Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
    J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
    Vercellino L; Bousquet G; Baillet G; Barré E; Mathieu O; Just PA; Desgrandchamps F; Misset JL; Hindié E; Moretti JL
    Cancer Biother Radiopharm; 2009 Feb; 24(1):137-44. PubMed ID: 19243256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib.
    Cleary JM; Sadow PM; Randolph GW; Palmer EL; Lynch TP; Nikiforov YE; Wirth LJ
    J Clin Oncol; 2010 Aug; 28(23):e390-2. PubMed ID: 20567012
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
    Mucha SA; Kunert-Radek J; Pomorski L
    Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
    Kelly-Morland C; Rudman S; Nathan P; Mallett S; Montana G; Cook G; Goh V
    BMC Cancer; 2017 Jun; 17(1):392. PubMed ID: 28578690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.